Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude comparant le Siplizumab au globuline anti-thymocyte de lapin pour aider l'organisme à accepter une greffe de rein (MODERNIZE1)

6 novembre 2026 mis à jour par: ITB-Med LLC

Étude de phase 2b, randomisée, multicentrique, en double aveugle, de recherche de dose, contrôlée active, du siplizumab (TCD601) comparé à la globuline anti-thymocytes de lapin chez des receveurs de greffe rénale nécessitant un traitement d’induction et recevant un traitement immunosuppresseur standard avec du tacrolimus, de l’acide mycophénolique et des corticostéroïdes

The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease. The main questions it aims to answer are:

How many adverse events do participants receiving two different doses of siplizumab have compared to rabbit anti-thymocyte globulin (rATG)?

How many participants successfully keep their kidney transplant after receiving siplizumab or rATG? This will be calculated as those participants that did not: die; have their kidney fail to work properly (graft loss); their body rejects their transplant (tissue sample (biopsy)-proven acute rejection: BPAR); or who were lost to follow-up.

How does the body respond to siplizumab after dosing at each of the 2 dose levels?

How does siplizumab work in the body compared to rATG?

Selected participants will be divided into 3 groups. In 2 of the groups, participants will be given siplizumab at one of the two study medicine doses. Participants in the third group will be given rATG. All participants will take the usual anti-rejection medicines given before, during, and after a kidney transplant. All participants will also be given medicines before the study drug to lower the risk of reactions, and medicines used to prevent or treat infections after the transplant.

Participants will be asked to provide their medical history at the first visit at the study site where you will have your kidney transplant. At the first visit and other visits participants will be asked to provide their medication history, have a physical exam, check vital signs, have blood drawn for tests, and have non-invasive tests that record the electrical activity of your heart (ECG) and blood draws.

Participants will be monitored for 12 months after transplant surgery.

Aperçu de l'étude

Description détaillée

Approximately 120 renal transplant candidates requiring induction therapy will be enrolled 1:1:1 to receive 1 of 2 dose levels of siplizumab or to the comparator rATG.

Randomization will be stratified by donor status (living vs donation after brain death vs donation after cardiac death) to ensure similar proportions of donor types in each study arm. All participants will also receive:

  • A triple regimen (TAC, MPA, and CS) of background immunosuppressive therapy for the duration of the study.
  • Premedication prior to study treatment infusions.
  • Infection prophylaxis

This clinical trial will evaluate the safety of an anti-cluster of differentiation 2 (CD2) monoclonal antibody, siplizumab, compared to rATG as induction therapy in renal transplant recipients.

Following hospital discharge, participants will undergo assessments and procedures as indicated in the protocol through Month 12 or EOS, unless more frequent visits are required per local SoC or for laboratory specimen collection.

Safety assessments will include physical examinations, ECGs, vital signs, viral surveillance and monitoring, standard clinical laboratory evaluations completed centrally (hematology, clinical chemistry, urinalysis), and AE/SAE monitoring.

Final analysis will be performed when all participants have completed 12-month follow-up visits post-transplant or have otherwise ended the trial. This analysis will be performed to evaluate the safety of siplizumab at 2 dose levels compared to rATG.

Type d'étude

Interventionnel

Inscription (Estimé)

120

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Brésil, 30150-320
        • Recrutement
        • Santa Casa Demisericordia de Belo Horizonte
        • Contact:
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brésil, 90035-903
        • Recrutement
        • Hospital de Clinicas de Porto Alegre
        • Contact:
      • Porto Alegre, Rio Grande do Sul, Brésil, 90020-090
        • Recrutement
        • Santa Casa de Misericordia de Porto Alegre - Hospital Dom Vincente Scherer
        • Contact:
    • São Paulo
      • São José do Rio Preto, São Paulo, Brésil, 15090-000
        • Recrutement
        • Fundação Faculdade Regional de Medicina de São José do Rio Preto - Centro Integrado de Pesquisa
        • Contact:
      • São Paulo, São Paulo, Brésil, 04038-002
        • Recrutement
        • Fundação Oswaldo Ramos - Hospital do Rim (HRIM)
        • Contact:
      • Barcelona, Espagne, 08035
        • Recrutement
        • Hospital Universitari Vall D'Hebron
        • Contact:
      • Córdoba, Espagne, 14004
      • Málaga, Espagne, 29010
        • Recrutement
        • Hospital Universitario Regional de Malaga
        • Contact:
    • California
      • Los Angeles, California, États-Unis, 90033
        • Recrutement
        • Keck Hospital of the University of Southern California
        • Contact:
      • Los Angeles, California, États-Unis, 90095
        • Recrutement
        • University of California - Los Angeles, Connie Frank Kidney Transplant Center
        • Contact:
      • Sacramento, California, États-Unis, 95817
        • Recrutement
        • UC Davis Medical Center
        • Contact:
    • Florida
      • Tampa, Florida, États-Unis, 33606
        • Recrutement
        • Tampa General Hospital
        • Contact:
    • Georgia
      • Atlanta, Georgia, États-Unis, 30322
        • Recrutement
        • Emory University Hospital
        • Contact:
    • Kansas
      • Kansas City, Kansas, États-Unis, 66160
        • Recrutement
        • University of Kansas Hospital
        • Contact:
    • Kentucky
      • Lexington, Kentucky, États-Unis, 40536
        • Recrutement
        • University of Kentucky Healthcare
        • Contact:
    • Louisiana
      • Metairie, Louisiana, États-Unis, 70006
        • Recrutement
        • Tulane Medical Center
        • Contact:
    • Massachusetts
      • Worcester, Massachusetts, États-Unis, 01655
    • Michigan
      • Ann Arbor, Michigan, États-Unis, 48109
        • Recrutement
        • University of Michigan - Michigan Medicine
        • Contact:
          • Nerissa Reister, Clinical Research Coordinator
          • Numéro de téléphone: 734-763-5718
          • E-mail: naflow@med.umich.edu
      • Detroit, Michigan, États-Unis, 48202
        • Recrutement
        • Henry Ford Health
        • Contact:
    • New Jersey
      • Livingston, New Jersey, États-Unis, 07039
        • Recrutement
        • Cooperman Barnabus Medical Center
        • Contact:
    • New York
      • New York, New York, États-Unis, 10032
        • Recrutement
        • New York Presbyterian - Columbia University Irving Medical School
        • Chercheur principal:
          • Lloyd Ratner, MD
        • Contact:
        • Contact:
      • New York, New York, États-Unis, 10065
        • Recrutement
        • New York Presbyterian - Weill Cornell Medical Center
        • Contact:
          • Jennifer Lee
          • Numéro de téléphone: 212-746-0192
          • E-mail: jel9109@nyp.org
        • Contact:
    • North Carolina
      • Durham, North Carolina, États-Unis, 27710
        • Recrutement
        • Duke University Medical Center
        • Contact:
    • Texas
      • Dallas, Texas, États-Unis, 75390
    • Virginia
      • Falls Church, Virginia, États-Unis, 22042
        • Recrutement
        • Inova Fairfax Hospital
        • Contact:
      • Richmond, Virginia, États-Unis, 23298
        • Recrutement
        • Virginia Commonwealth University Health
        • Contact:
    • Washington
      • Seattle, Washington, États-Unis, 98195
        • Recrutement
        • University of Washington Medical Center
        • Contact:
          • Belinda Pan, Research Coordinator
          • Numéro de téléphone: 206-598-1562
          • E-mail: bcpan@uw.edu

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 70 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Recipients of a renal allograft from a non-HLA identical living or deceased donor.
  • Recipients of a kidney with a cold ischemia time < 30 hours; hypothermic machine perfusion within the same timeframe is acceptable.
  • Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, must agree to use highly effective methods of contraception.

Exclusion Criteria:

  • Transplant recipients seronegative for EBV.
  • Transplant recipients receiving a kidney from a non-heart beating donor (ie, DCD) whose organ is retrieved from an uncontrolled DCD or whose donor age > 55 years of age.
  • Multi-organ transplant recipients (eg, kidney-pancreas, organ other than kidney), dual-kidney transplant recipients, recipients with more than one prior kidney transplant, or hematopoietic stem cell transplantation recipients.
  • Presence of current or historical DSA via single-antigen bead assay or local SoC. The MFI cut-off value used to determine the presence of DSA will be defined as per the institutional SoC. Results within 3 months prior to transplant are acceptable.
  • Crossmatch positive (isolated positive B cell crossmatches are not an exclusion criterion).
  • ABO-incompatible recipient.
  • Administration of complement inhibitor therapy within 6 months prior to the transplant, or likely to require treatment with complement inhibitor therapy during the study.
  • Participants receiving immunosuppressive therapies prior to transplant for pre-existing conditions must be candidates for the protocol-defined regimen.
  • History of malignancy of any organ system, except for localized excised non-melanomatous skin lesions or carcinoma in situ of the cervix.
  • Seropositive for human immunodeficiency virus or hepatitis B surface antigen. Participants who are seropositive for hepatitis C virus (HCV) are excluded without proof of sustained viral response after anti-HCV treatment.
  • Recipient of a kidney from a donor who tests positive for human immunodeficiency virus or hepatitis B surface antigen/hepatitis B core protein.
  • History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (eg, siplizumab, rATG, TAC, MPA derivatives, CS).
  • Evidence of active tuberculosis (TB) infection (participants with a history of latent TB may become eligible after treatment with anti-TB therapy according to national guidelines).
  • Participants with severe systemic infection(s), at the time of screening or within 2 weeks prior to randomization

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Siplizumab à faible dose

A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class

Autres noms:
  • TCD601
Expérimental: Siplizumab à haute dose

A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class

Autres noms:
  • TCD601
Comparateur actif: Globuline anti-thymocyte de lapin

An anti-human thymocyte immunoglobulin preparation made of purified polyclonal antibodies derived from rabbits

Autres noms:
  • Thymoglobuline

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Assessment of the safety of 2 dose levels of siplizumab versus rATG.
Délai: 12 months

Number and percentage of participants at 12 months post-transplant experiencing adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs).

12 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Délai: 12 months
  • Composite incidence of BPAR, death, graft loss, and loss-to-follow-up.
  • Incidence of participants who experienced BPAR as defined by central pathology (blinded independent central review using Banff Allograft Pathology Scoring).
  • Incidence of treated BPAR and steroid-resistant BPAR.
12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Délai: 12 months

• Grade of BPAR.

12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Délai: 12 months

• Severity of BPAR.

12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Délai: 12 months
  • Time to first BPAR for each participant.
  • Time to graft loss for each participant.
  • Time to death for each participant.
12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Délai: 12 months
  • Participant survival at 12 months.
  • Graft survival at 12 months.
12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Délai: 12 months

• Number of participants requiring for-cause renal allograft biopsy assessments over 12 months post-transplant.

12 months
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
Délai: 12 weeks

Siplizumab Cmax (maximum blood concentration) over 12 weeks post-transplant.

12 weeks
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
Délai: 12 weeks

Siplizumab AUC (area under the concentration-time curve) over 12 weeks post-transplant.

12 weeks
Assessment of the pharmacodynamics (PD) of 2 dose levels of siplizumab versus rATG.
Délai: 12 months

Depletion and recovery of lymphocyte count by subset (total lymphocytes; CD3+, CD4+, and CD8+ T cells; CD19+ B cells; CD56+ NK cells) over 12 months post-transplant.

12 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

29 juin 2026

Achèvement primaire (Estimé)

28 mars 2028

Achèvement de l'étude (Estimé)

28 mars 2028

Dates d'inscription aux études

Première soumission

11 mars 2026

Première soumission répondant aux critères de contrôle qualité

27 mars 2026

Première publication (Réel)

2 avril 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

6 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner